Neutropenia  >>  epirubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
NCT01611051: A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Completed
3
330
RoW
Drug: Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg, rhG-CSF 5ug/kg/day
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Neutropenia, Febrile Neutropenia
01/13
 
GeparOcto, NCT02125344 / 2014-000619-14: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer

Completed
3
961
Europe
non-pegylated liposomal doxorubicin, Myocet, Carboplatin, Carbomedac, Paclitaxel, var., Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Ferric carboxymaltose, Ferinject
German Breast Group, Amgen, Roche Pharma AG, Teva Pharmaceuticals USA, Vifor Pharma
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
11/16
01/17
COMPETE, NCT02532400: Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

Terminated
3
21
RoW
Neoadjuvant endocrine therapy, Goserelin and AI, Neoadjuvant chemotherapy, TEC
Ruijin Hospital
Breast Cancer
03/19
03/19
TCTN, NCT02455141: Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer

Recruiting
3
970
RoW
Epirubicin plus Cyclophosphamide, EC, Taxanes, Taxanes plus Carboplatin
Shanghai Jiao Tong University School of Medicine
Breast Neoplasm
12/22
12/23
2011-001462-17: Trial for the optimisation of risk assessment and therapy success predicition in patients with early breast cancer by the use of biomarkers in advance to therapy decission-making to personalize therapies.

Ongoing
2/3
5236
Europe
Epirubicin, Cyclophosphamide, Paclitaxel, Tamoxifen, Anastrozole, Letrozole, Exemestan, trastuzumab emtansine (T-DM1), Trastuzumab, Paclitaxel-Albumin, Gemcitabine, Carboplatin, Pertuzumab, Myocet, RO530-4020/xxx, RO4368451, Concentrate for solution for infusion, Tablet, Powder for concentrate for solution for infusion, Powder for solution for infusion, Kadcyla, Herceptin 150 mg, Abraxane, Perjeta
Westdeutsche Studiengruppe GmbH, Genomic Health , Inc., Roche Pharma AG, Celgene Corp., Amgen, TEVA GmbH, Bayer AG
Early primary breast cancer, hormone receptor positve or negative, HER2 positive or negative, any nodal status., Early diagnosed breast cancer at first occurence, with hormone receptor over-expressing tumor and any lymph node involvement (from none to any)., Diseases [C] - Cancer [C04]
 
 

Download Options